Published in Cancer Weekly, January 29th, 2008
In this triple analysis report the author has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Melanoma, and NSCLC, which are all subjects to an extensive number of innovative drug candidates. This extensive 450+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.